Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Common Equity (2016 - 2025)

Veracyte's Common Equity history spans 14 years, with the latest figure at $1.3 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 11.36% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $1.3 billion, up 11.36%, while the annual FY2025 figure was $1.3 billion, 11.36% up from the prior year.
  • Common Equity for Q4 2025 was $1.3 billion at Veracyte, up from $1.3 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.3 billion in Q4 2025 and bottomed at $971.2 million in Q2 2021.
  • The 5-year median for Common Equity is $1.1 billion (2021), against an average of $1.1 billion.
  • The largest annual shift saw Common Equity soared 329.45% in 2021 before it decreased 5.32% in 2022.
  • A 5-year view of Common Equity shows it stood at $1.1 billion in 2021, then decreased by 1.94% to $1.1 billion in 2022, then decreased by 2.89% to $1.0 billion in 2023, then increased by 12.63% to $1.2 billion in 2024, then increased by 11.36% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Common Equity are $1.3 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.2 billion (Q2 2025).